Sections
1. Investment Snapshot
2. Price Chart
3. Thesis
4. Valuation & Price Target
5. Business & Product Moat
6. People & Governance
7. Market & Macro
8. Financial Quality
9. Risk Register
Discussion
Investment Snapshot
Price Chart
Thesis
Valuation & Price Target
Business & Product Moat
People & Governance
Market & Macro
Financial Quality
Risk Register
Discussion
Mobia Medical, Inc.
Investment Snapshot
Symbol
MOBI
IPO Date (Actual)
2026-05-08
Offer Range
$15.00
Shares Offered
10.0M
Total Shares Post-IPO
43.1M
Market Cap
—
Target Price
$00.00Implied Upside vs Midpoint
$00.00Use of Proceeds
Net proceeds (~$134.5M at the $15 midpoint after underwriting discounts/expenses) to fund commercial expansion (direct salesforce), additional clinical evidence generation, and general corporate purposes.
Mobia Medical (proposed ticker MOBI) is an early commercial medtech company marketing the FDA‑approved Vivistim Paired VNS system for post‑stroke upper‑limb rehabilitation. The IPO price range is $14.00–$16.00 for 10.0M shares (plus up to 1.5M overallotment), implying pro forma market cap of ~$496M at the $15 midpoint and roughly $529M at $16 on ~33.09M pro forma shares.
○
Product: Vivistim Paired VNS — implanted IPG, lead, clinician software; FDA PMA (2021).○
2025 revenue: $32.0M (vs $15.6M in 2024); company is commercial stage with direct salesforce and market access team.Price Chart
Historic Price Chart - MOBI
Thesis
Target price: $15.00. Implied upside downside vs offer midpoint: $0 (priced at the $15.00 midpoint). Key multiple: implied Price Sales ≈ 15.5x (pro forma market cap ≈ $496M / 2025 revenue $32.0M at $15 midpoint). Key catalyst: expanded payer coverage that converts insurers from “experimental” to reimbursed status and rapid growth in hospital implant volumes. Key risk: single‑product concentration plus limited payor coverage and an identified material weakness in internal controls that could force dilutive financings and impair execution.
Mobia represents a high‑risk, high‑upside pure play in implantable neuromodulation: PMA approval and early commercial traction underpin significant upside if payer coverage and hospital adoption accelerate. The core long case depends on conversion of payors from investigational to covered status, expanding implant volumes, and publication of longer‑term clinical outcomes to drive durable adoption.
○
Large addressable U.S. population cited (~1M chronic ischemic stroke survivors with moderate‑to‑severe impairment).○
Revenue roughly doubled from 2024 to 2025, signaling early commercial uptake.○
De‑risking path is executional (coverage, scale, evidence) rather than technological.Valuation & Price Target
████████████████████
Implied price sales ≈ 15.5x at $15 midpoint.
At the $15 midpoint the offering implies a pro forma market cap of roughly $496M versus trailing 2025 revenue of $32.0M, implying a price sales multiple (~15.5x). Given the company's single‑product profile and execution risk, the valuation reflects expectations for continued rapid growth and payer expansion; the stock will likely re‑rate on clear reimbursement wins and sustained implant volume growth.
○
Implied market cap at $15 midpoint ≈ $496M; at $16 ≈ $529M.○
Implied P S (pro forma) ≈ 15.5x on 2025 revenue $32.0M.Business & Product Moat
████████████████████
Company Description (Source)
We are a commercial-stage medical device company redefining stroke recovery for
survivors living with life-altering motor impairments. Our Vivistim Paired Vagus
Nerve Stimulation (Paired VNS) System is the first and only
clinically-validated, FDA-approved solution for chronic ischemic stroke
survivors with moderate to severe upper extremity impairments. Stroke is one of
the leading causes of long-term disability in the United States. While
advancements in acute stroke care over the past decade have significantly
reduced mortality, innovation for chronic stroke recovery has lagged, resulting
in a growing number of stroke survivors living with meaningful impairments. Our
breakthrough Vivistim Paired VNS System (Vivistim System) addresses this unmet
need. The Vivistim System includes an implanted pulse generator and lead that
deliver stimulation to the vagus nerve when activated. During treatment
(Vivistim Therapy), intentional bursts of stimulation are delivered during
functional movement to increase neuroplasticity and durably restore motor
function. Clinical data has demonstrated that Vivistim Therapy delivers
meaningful improvements in upper limb function, which can help stroke survivors
regain critical capabilities and independence and restore quality of life,
regardless of the time elapsed since the patient’s stroke. We believe we are
setting a new standard of care in chronic stroke recovery, facilitating a new
treatment pathway for chronic ischemic stroke survivors with moderate to severe
upper extremity impairments. We have experienced rapid growth since our full
commercial launch in 2023, and physicians have performed over 1,000 implants,
including approximately 700 in 2025.
In the United States, a stroke occurs every 40 seconds and approximately 800,000
strokes occur annually, according to a report published by the American Heart
Association (AHA) in 2025. Stroke occurs when blood flow to a region of the
brain is suddenly interrupted, either because an artery becomes blocked in the
case of an ischemic stroke, or because a weakened blood vessel ruptures in the
case of a hemorrhagic stroke. For stroke survivors, the interruption of blood
flow to the brain can result in lasting motor, cognitive, visual, and language
impairments, including weakness or hemiparesis affecting the extremities. Based
on a report published by the AHA in 2025, we estimate that there are currently
approximately 10 million stroke survivors in the United States, the majority of
whom are living with chronic impairments.
Chronic ischemic stroke is a serious medical condition characterized by physical
and cognitive impairments that persist beyond the first three to six months
post-stroke. These impairments can materially diminish a patient’s independence
and quality of life. According to a report published by the AHA in 2025,
ischemic stroke is a leading cause of serious long-term impairment for adults in
the United States and has an estimated annual healthcare burden of more than $25
billion.
Chronic stroke recovery presents a significant market opportunity. According to
the AHA, approximately 87% of the strokes in the United States are ischemic.
This equates to approximately 9 million ischemic stroke survivors in the United
States, of which we estimate that more than 4 million are chronic ischemic
stroke survivors living with moderate to severe upper extremity impairment. This
population falls within the current on-label indication for the Vivistim System.
We believe that an initial market opportunity comprises approximately 1 million
of those survivors that demonstrate the requisite overall health, cognition and
motivation to participate in therapy and have received some amount of
post-stroke therapy, which we estimate represents an initial market opportunity
of over $30 billion based on the average selling price of the Vivistim System.
Vivistim Therapy is effective for recent stroke survivors as well as patients
who initiate treatment many years post-stroke. Based on a report published by
the AHA in 2025, we estimate that each year approximately 200,000 new stroke
survivors in the United States meet our indication for use, with 50,000 of these
survivors representative of our initial market opportunity.
There is no standard of care for motor recovery in the chronic stage of stroke.
After the initial three- to six-month sub-acute phase post-stroke, patients
typically reach a functional plateau with conventional physical rehabilitation
and have limited options to continue improving. As a result, we believe that
there is a large population of highly motivated stroke survivors who have few
proven options.
Our breakthrough Vivistim System is the first and only FDA-approved solution for
chronic ischemic stroke survivors with moderate to severe upper extremity
impairments. The Vivistim System facilitates Vivistim Therapy, which has been
clinically proven to significantly improve upper limb function and help patients
regain critical capabilities and independence. Vivistim Therapy leverages
neuroplasticity – the ability of the nervous system to adapt and reorganize its
connections – to improve upper limb function in patients with chronic stroke.
The Vivistim System includes an implantable device that stimulates the vagus
nerve only when intentionally activated, triggering the release of
neuromodulators. These neuromodulators create a heightened state of plasticity
in the brain, such that neural networks can more readily adapt and reform in
response to stimuli. When functional movements, such as goal- or task-oriented
exercises and movements, are performed in the presence of these increased
neuromodulators, the brain can create new neural connections and strengthen
existing connections to a degree that would otherwise not be possible, enabling
lasting improvements in motor pathways and creating greater potential for
recovery.
Shortly after device implantation, patients begin Vivistim Therapy with a
physical or occupational therapist. This therapy does not require
patient-specific programming. In the clinic, the therapist uses a remote to
activate the Vivistim System during task-specific practice, such as reaching for
and grasping objects. Patients continue Vivistim Therapy at home, both during
their in-clinic therapy protocol and, if desired, in the months and years that
follow. At home, patients easily activate stimulation sessions by swiping the
Vivistim magnet over the Vivistim implanted pulse generator (IPG) implant site,
which initiates 30 minutes of periodic stimulation pulses. Patients can perform
this therapy at home or during their activities of daily living to further
reinforce their neural retraining. We believe the ability for patients to
observe real, tangible improvements in their ability to perform activities of
daily living can encourage ongoing engagement with at-home therapy, helping
patients to sustain their efforts and achieve meaningful, lasting functional
improvement over time.
We believe we are setting a new standard of care in chronic stroke recovery,
facilitating a new treatment pathway for chronic ischemic stroke patients with
moderate to severe upper extremity impairment. We believe Vivistim Therapy
offers these patients a number of key benefits, including the first and only
FDA-approved device clinically proven to deliver significant improvements in
upper limb function; significant clinical improvement even for patients who
initiate treatment many years post-stroke; durable improvements underpinned by a
clinically proven mechanism of action; high patient and therapist satisfaction;
and a safe and minimally invasive outpatient procedure.
We are building a robust body of clinical evidence supporting the safety,
efficacy, durability, and well-understood mechanism of action of Vivistim
Therapy, with additional trials ongoing and planned in 2026 and beyond. In our
pivotal, triple-blind, randomized, sham-controlled VNS-REHAB trial, Vivistim
Therapy resulted in an approximately two-times greater, as measured by
Fugl-Meyer Assessment of Upper Extremity (FMA-UE), and approximately three-times
greater, as measured by Wolf Motor Function Test (WMFT), improvement in hand and
arm function compared to intensive rehabilitation alone, at the end of the
in-clinic and at-home therapy protocol. Data from the trial also demonstrated a
favorable safety profile, with no severe adverse events, serious adverse events
or unanticipated adverse events associated with the Vivistim System. While
implantation can result in procedure-related complications, such as
post-operative pain and infection, the rate of surgical complications that did
not resolve within a few weeks was less than 1% in the VNS-REHAB trial. These
results highlight Vivistim Therapy’s distinctive ability to drive substantial
neuroplastic adaptations and functional gains, which we believe sets it apart as
the only therapy with robust clinical evidence for effective post-stroke motor
recovery. Looking ahead, our GRASP registry is collecting real-world evidence to
reinforce the durable benefits of Vivistim Therapy. We believe patient access is
key to gaining market acceptance, and we remain committed to expanding patient
access by developing additional evidence that further validates the benefits of
Vivistim Therapy, accelerates market adoption, strengthens proof of its clinical
utility, and supports broader reimbursement coverage decisions.
We continue to optimize our commercial model to support the adoption of Vivistim
Therapy and gain further market acceptance. Our strategy is tailored to our
unique patient and customer dynamics. Stroke survivors living with life-altering
functional impairment can self-identify and are highly motivated to seek
effective, long-lasting solutions. These patients are often supported by
dedicated advocates who create a strong network of care and commitment. Our
target customer base consists of a highly concentrated group of approximately
1,500 primary and comprehensive stroke centers in the United States, which are
hospitals that have cross-functional teams with the capabilities to treat acute
stroke at the highest level of care and in compliance with AHA guidelines. These
stroke centers, which are typically surrounded by a network of therapy sites
with neurorehabilitation capabilities, provide the infrastructure for efficient
implementation of Vivistim Therapy.
As a novel treatment, expanding market acceptance depends in part upon our
ability to educate healthcare providers and others as to the distinctive
characteristics, clinical and benefits, safety, durability and ease of use of
Vivistim Therapy. We believe we have implemented highly effective initiatives
for generating a consistent funnel of Vivistim Therapy candidates through
physician and therapist referrals, as well as direct patient engagement. Stroke
survivors interact with a diverse network of care providers who help identify
and evaluate candidates. We directly engage each of these stakeholders through
specialized events, summits, and conferences as well as through our field-based
commercial team. Our commercial organization is responsible for driving adoption
of the Vivistim System through customer outreach, education, and relationship
management activities. Our team includes Territory Managers (TMs), who support
initial customer onboarding efforts at stroke centers and maintain commercial
relationships with physicians and administrators, and Therapy Development
Specialists (TDSs), who focus on outreach to therapy sites and provide general
educational information regarding the clinical use of the Vivistim System. These
activities are intended to facilitate customer adoption and utilization of the
Vivistim System.
Our commitment to offering life-changing treatments drives our passion for
innovation through continuous research and development. We commenced development
efforts in 2007 with an aim to pursue initial research from the University of
Texas regarding the effects of vagus nerve stimulation. By early 2013, we began
focusing on paired vagus nerve stimulation therapy for stroke recovery, working
with a small team of fewer than ten engineers, clinicians and scientists. Over
several years, this work led to the development and clinical testing of our
Vivistim System, including through our feasibility, pilot and pivotal trials
from 2014 to 2021. Following the results of our pivotal trial, we submitted a
premarket approval (PMA) application to the FDA in March 2021. The Vivistim
System received PMA approval from the FDA in 2021 and is classified by the FDA
as a Class III device. In 2021, the Vivistim System was granted breakthrough
device status under the FDA’s Breakthrough Devices Program. We aim to build upon
these development efforts and leverage our internal expertise, clinical insights
and experience gained from developing the Vivistim System to assess and
prioritize research and development initiatives.
The Vivistim System implantation procedure falls under a long-established
Category 1 CPT code. Effective January 1, 2026, this CPT code was assigned to a
New Technology Ambulatory Payment Classification (APC) by the Centers for
Medicare and Medicaid Services (CMS), establishing an elevated payment level
that we believe will support sustainable access for Medicare beneficiaries.
Coverage for Vivistim Therapy varies by payor. As there are currently no
national coverage determinations or local coverage determinations specific to
Vivistim Therapy, coverage for Medicare fee-for-service patients is made on a
case-by-case basis and patients are typically able to access Vivistim Therapy
when medically necessary, without prior authorization. Currently, most
commercial insurers have determined that Vivistim Therapy is experimental or
investigational and therefore, not covered. To that end, commercial insurance,
Medicaid and Medicare Advantage generally require prior authorization. Our
in-house market access team supports providers by facilitating administrative
aspects of the prior authorization process, including assisting with
documentation and submissions to payors in advance of implantation. As part of
our longer term strategy, our market access team plans to continue to engage
with payors to communicate clinical and health economic data which may impact
coverage policies. We believe that expanded payor coverage will facilitate
broader patient access to Vivistim Therapy.
---
We were incorporated in Delaware on March 5, 2007 as MicroTransponder, Inc.
Effective February 23, 2026, we changed our name to “Mobia Medical, Inc.” Our
principal executive offices are located at 2802 Flintrock Trace, Suite 226,
Austin, TX 78738. Our telephone number is (855) 628-9375. Our website address is
www.mobia.com.
Competitor Set
████████████████████People & Governance
Richard Foust
CEO
As CEO of a single‑product, early commercial medtech company, Mr. Foust's execution credibility on commercialization and channel expansion is central to the investment case and will materially affect adoption and revenue trajectory.
Strengths
+
Prior roles include commercialization positions at Velano Vascular, Analyte Health and Abbott Vascular; CEO since January 2022; holds an M.S. in Mechanical Engineering (Bioengineering). Relevant hospital channel and product launch experience support his fit to scale Vivistim adoption.Weaknesses
−
No adverse open‑web findings surfaced in this run (web search disabled).Nelson Bunker Curnes
CFO, Director
As CFO, credibility on financial controls, capital management and public‑company reporting is a valuation lever given the filing's disclosed material weakness and the company's need for ongoing capital.
Strengths
+
CFO since September 2020; prior experience includes COO at TEGA Technologies and Principal at The Boston Consulting Group; holds a B.S. in Mechanical Engineering and an MBA. Experience spans operations, strategy and finance relevant to managing growth and capital raises.Weaknesses
−
No adverse open‑web findings surfaced in this run (web search disabled).Thomas Jordan Curnes II
Co‑founder, Director (expected to resign prior to IPO closing)
Founder transition is valuation‑relevant: the founder's resignation prior to closing reduces key‑person concentration risk but creates potential short‑term transition risk if institutional knowledge departs.
Strengths
+
Co‑founder and former President with a B.B.A. and MBA and historical operating knowledge of the business, indicating deep familiarity with product development and early commercialization.Weaknesses
−
No adverse open‑web findings surfaced in this run (web search disabled).Dana G. Mead, Jr.
Chair of the Board
Board chair experience at healthcare public companies supports governance and strategic advisory during the company’s commercial scale‑up and is valuation‑supportive for oversight of commercialization and regulatory strategy.
Strengths
+
Board leadership roles at Pulmonx, Inspire Medical, HeartFlow and prior CEO experience; MBA noted in the filing. Brings public company governance and sector expertise.Weaknesses
−
No adverse open‑web findings surfaced in this run (web search disabled).Casey Tansey
Director
Venture and board perspective can help align capital providers with commercialization strategy, a valuable governance facet for an early commercial medtech.
Strengths
+
General Partner at U.S. Venture Partners with extensive medtech investment and board experience, providing fundraising and go‑to‑market guidance.Weaknesses
−
No adverse open‑web findings surfaced in this run (web search disabled).William (Bill) Harrington, M.D.
Director
Clinical credibility on the board supports trial design, clinical evidence generation and physician adoption which are central to the company's path to reimbursement and adoption.
Strengths
+
Managing Partner at Osage University Partners with venture and board experience in medtech/biotech; holds an M.D. and an MBA, providing clinical and commercialization insight.Weaknesses
−
No adverse open‑web findings surfaced in this run (web search disabled).Cynthia Lucchese
Director
Public‑company CFO experience on the board is valuation‑positive for financial governance during and after the IPO and for remediation of the disclosed material weakness.
Strengths
+
Seasoned public company CFO and board member with healthcare/device finance experience; former CFO roles at Hulman, Hillenbrand and Thoratec as noted in the filing.Weaknesses
−
No adverse open‑web findings surfaced in this run (web search disabled).Maxwell Bikoff
Director
Investor representation on the board provides capital markets perspective useful for IPO execution, follow‑on financing strategy, and investor relations.
Strengths
+
Investor at Longitude Capital with medtech investment and board experience; holds a B.S.E. in Biomedical Engineering, aligning technical and investor perspectives.Weaknesses
−
No adverse open‑web findings surfaced in this run (web search disabled).Edward Hanlon
Director
Growth‑stage investing experience on the board supports oversight of clinical/commercial scaling and strategic financing decisions.
Strengths
+
Investment director at Gilde Healthcare with clinical and growth‑stage medtech investing experience relevant to scaling a single‑product device company.Weaknesses
−
No adverse open‑web findings surfaced in this run (web search disabled).Management includes experienced medtech commercial leaders and investors on the board; the founder is expected to step down pre‑IPO which reduces founder concentration risk but introduces transition risk. The filing discloses a material weakness in internal control that elevates governance focus for the CFO and audit committee post‑IPO.
○
CEO Richard Foust (commercialization experience) — CEO since Jan 2022.○
CFO Nelson Bunker Curnes — finance and operations experience; material weakness flagged in filing.○
Board chaired by Dana G. Mead, Jr., with multiple healthcare public‑company board experiences.Market & Macro
The market is defined by a large pool of chronic ischemic stroke survivors and hospital buyers (primary/comprehensive stroke centers). Payer dynamics and healthcare reimbursement policy are the key market levers; macro liquidity and IPO window conditions will affect aftermarket performance but are not detailed in the report.
○
Addressable U.S. population cited ≈ 1 million chronic ischemic stroke survivors (moderate‑to‑severe impairment).○
Adoption dependent on hospital procurement cycles and payer coverage decisions.Financial Quality
2025 gross margin ≈ 81.2%; revenue growth ~105 YoY (2024→2025).
Mobia reported revenue growth from $15.6M (2024) to $32.0M (2025) with materially positive gross profit ($25.98M in 2025) but widening operating losses driven by commercial scale‑up (operating loss (46.4)M in 2025). The company has a modest cash balance pro forma but negative equity and an accumulated deficit, indicating ongoing financing needs.
Risks
−
Operating loss: (24.2)M (2024) → (46.4)M (2025).Observations
○
Revenue: $15.6M (2024) → $32.0M (2025).○
Gross profit: $12.45M (2024) → $25.98M (2025); gross margins ~80 in 2025.○
Cash & equivalents: $14.6M (2024) → $33.6M (2025).Risk Register
Single‑product concentration and limited payor coverage: failure to convert insurers from investigational to reimbursed coverage would constrain adoption and revenue.
Material weakness in internal controls over financial reporting increases near‑term governance and operational risk and may impede timely public reporting.
Ongoing operating losses and need for additional capital,: which could be dilutive if commercial scale‑up is slower than expected.
Primary downside risks are reimbursement failure, single‑product concentration, execution risk in commercial scaling, an identified material weakness in financial reporting controls, and the need for future capital raises which could be dilutive.
Risks
−
Material weakness in internal control over financial reporting increases governance risk and may affect investor confidence.Observations
○
Payor coverage: many insurers consider therapy experimental; failure to expand coverage materially limits addressable demand.○
Single‑product dependence; product failure, safety or competitive displacement would be highly damaging.